Magenta Therapeutics Added to Russell 2000 and 3000 Indexes

From Startup Magenta Therapeutics

Link to Full Article:

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 24, 2018–
Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company
developing novel medicines to bring the curative power of bone marrow
transplant to more patients, today announced that the company has been
added to the Russell 2000 and 3000 indexes following the Russell U.S.
Indexes’ quarterly update.

The Russell 3000 index includes the 3,000 largest U.S. companies by
market capitalization. Membership in the Russell 3000® Index
means automatic inclusion in the large-cap Russell 1000® Index
or small-cap Russell 2000® Index as well as the
appropriate growth- and value-style indexes. Russell U.S. Indexes are
part of FTSE Russell, a leading global index provider, which determines
membership for its Russell U.S. Indexes primarily by objective,
market-capitalization rankings and style attributes.

Russell U.S. Indexes are widely used by investment managers and
institutional investors as the basis for index funds and as benchmarks
for active investment strategies. Approximately $9 trillion in assets
are benchmarked against Russell U.S. Indexes.

For more information on the Russell Indexes, please visit the “Russell
Reconstitution” section on the FTSE Russell website at

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a
clinical-stage biotechnology company developing an integrated portfolio
of therapeutics focused on critical areas of unmet need in the field of
bone marrow transplant for patients with autoimmune diseases, blood
cancers and genetic diseases.

Forward-Looking Statement

This press release may contain forward-looking statements, including
express or implied statements regarding Magenta’s future expectations,
plans and prospects, including projections regarding future revenues and
financing performance, our long-term growth, the anticipated timing of
our clinical trials and regulatory filings, the development of our
product candidates and advancement of our preclinical programs, as well
as other statements containing the words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” might,”
“plan,” “potential,” “project,” “should,” target,” “will” or “would” and
similar expressions constitute forward-looking statements under the
Private Securities Litigation Reform Act of 1995. Although Magenta’s
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Magenta. As a result, you are cautioned not to rely
on these forward-looking statements. These and other risks concerning
Magenta’s programs and operations are described in additional detail in
its registration statement on Form S-1, its Quarterly Report on Form
10-Q and its other filings made with the Securities and Exchange
Commission from time to time. Any forward-looking statement made in this
press release speaks only as of the date on which it is made. Magenta
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future developments or otherwise.

View source version on
Source: Magenta Therapeutics

Magenta Therapeutics:Manisha Pai, 857-242-1155Vice
President, Communications & Investor

Please visit their site for more information: Magenta

All,Biotechnology,Healthcare News,Startup News
2018-09-24 20:07:46